Bioanalysis, a leading MEDLINE indexed journal for bioanalysts, has published a Special Focus Issue on 'Bioanalysis of Biopharmaceuticals'. The journal is published by Future Science Group.
Biopharmaceuticals are gaining interest as new therapeutic agents and as technology progresses; they continue to increase in complexity, placing increasing expanding demand for bioanalytical capability to assess drug pharmacology, safety and immunogenicity.
The Special Focus Issue, guest Edited by Yan J Zhang (Bristol-Myers Squibb, NJ, USA) and Hyun Joo An (Chungnam National University, Daejeon, Korea), explores the recent advances in the analysis and development of biopharmaceuticals, through original research articles, as well as expert perspectives in the form of editorial and review style articles.
Yan J Zhang commented, "Empowered by innovation and shaped by regulation, bioanalysis technologies and strategies have evolved rapidly to enable development of new drug modalities and therapeutic approaches. This Special Focus Issue keeps bioanalytical scientists and regulatory agencies updated on the recent advances in technologies and strategies to address both bioanalytical capability and capacity gaps in support of emerging complex biopharmaceuticals and biosimilars."
"I am delighted to have worked with experts in the field to produce this timely and comprehensive Special Focus Issue discussing the challenges, advancements and novel strategies in the Bioanalysis of Biopharmaceuticals" said Sankeetha Nadarajah, Editor of the journal.
###
To read the full issue, please visit http://www.future-science.com/toc/bio/9/18
About Bioanalysis
Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 7,500 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews and commentaries. Membership is completely free of charge. Sign up online at: http://www.bioanalysis-zone.com/register.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. http://www.futuresciencegroup.com.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com.
Journal
Bioanalysis